COMMUNIQUÉS West-GlobeNewswire

ABBYY Introduces PHOENIX Plus, Advanced AI Models Optimized for Intelligent Document Processing
20/10/2026
PHOENIX Plus expands automation to any document type while improving accuracy and straight-through processing rates AUSTIN, Texas, Oct. 20, 2026 (GLOBE NEWSWIRE) -- ABBYY introduces PHOENIX Plus , a native generative AI [...]
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
20/10/2026
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the [...]
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
20/10/2026
– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient’s Skin Improved [...]
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study
20/10/2026
Expansion Stage to Compare Opamtistomig Plus Chemotherapy Head-to-Head With Tislelizumab Plus Chemotherapy in Previously Untreated Disease NANJING, China, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd [...]
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
20/10/2026
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0. [...]
Orikine Presents Preclinical Data Demonstrating Sustained Myeloid Reprogramming and Disease Control with ORK1 in Inflammatory Bowel Disease at UEG Week 2026
20/10/2026
A single dose of ORK1 generated durable disease control in two independent inflammatory bowel disease mouse models ORK1 induced sustained myeloid reprogramming, regulating chronic inflammation This data supports further [...]
KFSH Brings Cardiac Catheterization Directly to Emergency Department to Accelerate Critical Care
20/10/2026
RIYADH, Saudi Arabia, Oct. 20, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has established a dedicated Cardiac Catheterization Lab within the Emergency Department at its Riyadh [...]
Maxion Therapeutics Appoints Biopharma Leader Mikael Dolsten to Board of Directors
20/10/2026
Former Pfizer Chief Scientific Officer and President of Worldwide Research, Development and Medical brings deep experience translating scientific innovation into life-changing medicines for patients CAMBRIDGE, United [...]
Aqua free expands its product portfolio: New Baclyser® neo T Max offers greater capacity and efficiency
20/10/2026
Hamburg, Germany, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Hamburg, 20.10.2026 – Aqua free introduces the new Baclyser® neo T Max , the latest addition to its established Baclyser® neo range of sterile water filters. This [...]
Aqua free élargit sa gamme de produits : le nouveau Baclyser® neo T Max pour une capacité et une efficacité accrues
20/10/2026
Hamburg, Germany, 20 oct. 2026 (GLOBE NEWSWIRE) -- Hambourg, [date] – Avec le nouveau Baclyser® neo T Max , Aqua free présente la toute dernière évolution de sa gamme éprouvée de filtres stériles Baclyser® neo . Ce [...]
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
20/10/2026
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio REYKJAVIK, Iceland and LONDON, UK (October 20, 2026) - Alvotech (NASDAQ: ALVO [...]
Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch
20/10/2026
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech ( [...]
Transactions in connection with share buy-back program
20/10/2026
Company announcement no. 40 - 26 20 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors
20/10/2026
-- Mr. Astley-Sparke brings more than two decades of biotech leadership, having scaled several highly innovative transatlantic companies, including Replimune, uniQure and BioVex -- Dr. Sandor brings more than 20 years [...]
Gesynta Pharma completes enrollment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis
20/10/2026
Enrollment completed three months ahead of schedule NOVA is evaluating vipoglanstat, a novel, non-hormonal, non-opioid drug candidate for the treatment of endometriosis Topline data anticipated in Q2 2027 STOCKHOLM, Oct [...]
AltruBio Presents Phase 2a Data of ALTB-268 in Advanced Therapy-Refractory Ulcerative Colitis at UEG Week 2026
20/10/2026
Dose-related clinical activity: Week 12 clinical remission of 23.1% (3/13) in higher-dose Cohort 2 vs. 11.4% (4/35) in lower-dose Cohort 1 38.9% (7/18) of participants with a Day 29 trough concentration at or above the [...]
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
20/10/2026
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS [...]
Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million, Expanding its Rare Disease Pipeline and Gaining a European Base
20/10/2026
, Oct. 20, 2026 (GLOBE NEWSWIRE) -- CAMBRIDGE, UK & UTRECHT, THE NETHERLANDS – October 20, 2026 – Ambrose Healthcare, a rare disease specialist, has acquired 100% of the shares of AM-Pharma. Under the terms of the [...]
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
20/10/2026
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS [...]

Pages